FDA Reviewers Say Vorapaxar Approvable, But Question Study Changes
This article was originally published in The Pink Sheet Daily
Executive Summary
As the platelet inhibitor heads to an advisory committee, agency reviewers raise issues about safety-based changes to its Phase III trials.